Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Latest News

Ligand to Report Second Quarter Results on August 4th

Read More

Ligand Enters into OmniAb® Platform License Agreement with Gilead Sciences

Read More

Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
NASDAQ
Volume
Market Cap
Day Range
52-Week Range